+44 (0) 1223 755950
+1 832 327 7413
Icrucumab
REQUEST MORE INFO
Catalogue No: abx831212
Price:
US$464.00
(Size: 100 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Icrucumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FLT1/VEGFR-1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Research Articles on FLT1/VEGFR-1
| Target | FLT1/VEGFR-1 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Expression | Recombinant |
| Tested Applications | ELISA, WB |
| Host | Human |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Isotype | IgG1 Kappa |
| Form | Liquid |
| Purity | > 95% |
| Purification | Purified from cell culture supernatants by Protein A/G chromatography. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Buffer | 0.01 M PBS. pH 7.4. |
| CAS Number | 1024603-92-6 |
| Concentration | Batch-dependent, typically between 0.5-2.0 mg/ml. |
| Availability | Shipped within 7-12 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |